Personalis falls amid a downgrade as a competitive bid appears unlikely

Personalis falls amid a downgrade as a competitive bid appears unlikely
Personalis is said to have attracted takeover interest from Merck
1.69BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US71535D1063
CUSIP
71535D106
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
2.21
Dividend Share
-
Dividend Yield
-
Earnings Share
-1.09
Wall Street Target Price
15.17
EPS Estimate Current Year
-1.08
EPS Estimate Next Year
-0.97
EPS Estimate Current Quarter
-0.275
EPS Estimate Next Quarter
-0.2433
Most Recent Quarter
-
Revenue TTM
69,669,000
Gross Profit TTM
8,838,000
EBITDA
-104,596,000
Profit Margin
-153.84%
Return On Assets TTM
-25.03%
Return On Equity TTM
-50.32%
Revenue Per Share TTM
0.713
Qtly Revenue Growth YOY
30.00%
Diluted Eps TTM
-1.09
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
24.1595
Price Book MRQ
7.1916
Enterprise Value Revenue
21
Enterprise Value EBITDA
0
176.50
2.44%700.00
2.38%459.90
2.23%387.50
2.02%794.21
1.67%262.59
1.65%231.67
1.32%22.35
-3.50%669.85
-0.36%79.15
-0.20%